# FDHT PET and Bicalutamide in Metastatic Breast Cancer

> **NCT02697032** · PHASE2 · COMPLETED · sponsor: **University Medical Center Groningen** · enrollment: 22 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Bicalutamide
- **PROCEDURE:** FDHT PET

## Key facts

- **NCT ID:** NCT02697032
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2019-11-25
- **Final completion:** 2019-11-25
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2019-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02697032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02697032, "FDHT PET and Bicalutamide in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02697032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*